172 F. Supp. 3d 724
D.N.J.2016Background
- GSK owned U.S. Patent No. 4,602,017 covering lamotrigine (Lamictal) that expired July 22, 2008; Teva filed first-to-file paragraph IV ANDAs seeking to market generic lamotrigine (tablets and chewables).
- After a 2005 bench ruling invalidated one patent claim, GSK and Teva executed a February 16, 2005 settlement: Teva could sell GSK-supplied chewables in 2005 and agreed to delay launching generic tablets until July 21, 2008; GSK granted Teva an exclusivity-related waiver and agreed not to launch an authorized generic until January 2009.
- FDA approvals for Teva’s ANDAs occurred in 2006, but Teva delayed entry consistent with the settlement; Teva’s delayed entry effectively blocked other generics during its 180‑day exclusivity window.
- Indirect purchasers (named plaintiffs and classes) sued, alleging the settlement was an unlawful reverse-payment agreement that suppressed competition and inflated prices; they pleaded federal Sherman Act declaratory claims and multiple state-law antitrust, consumer-protection, and unjust-enrichment claims (New York, Michigan, California, and nationwide unjust enrichment).
- Defendants moved for judgment on the pleadings arguing (inter alia) the federal declaratory claims present no justiciable case or controversy, and all state-law claims are time‑barred or otherwise deficient; the court allowed Sherman Act declaratory claims to proceed but dismissed most state claims on statute‑of‑limitations and related grounds.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| 1) Are declaratory Sherman Act claims justiciable? | Plaintiffs seek declaratory relief that the settlement violated §§1–2 and argue injunctive/consumer harms suffice for Article III review. | Defendants contend declaratory claims are advisory because plaintiffs are indirect purchasers and lack a cognizable antitrust remedy. | Held: Justiciable. Indirect purchasers may seek equitable relief (Section 16) and plaintiffs plausibly allege threatened injury and proximate antitrust harm. |
| 2) Are New York Donnelly Act and GBL §349 claims timely (accrual/tolling)? | Plaintiffs assert fraudulent concealment/equitable tolling (including continued concealment of the No‑AG term) and continuing injury tolled accrual until 2012. | Defendants assert claims accrued when Teva received FDA approval and the settlement blocked competition (Aug 30, 2006); public filings and court records put plaintiffs on inquiry earlier. | Held: Time‑barred. Accrual occurred in 2006; continuing‑violation and equitable tolling doctrines do not save the claims given public disclosures and failure to plead specific concealment. |
| 3) Are Michigan Antitrust Reform Act claims timely and does plaintiff have standing under Michigan law? | Plaintiffs claim continuing harm and tolling under fraudulent concealment; class rep (IBEW Local 38) can represent Michigan purchasers. | Defendants argue accrual was 2006, tolling exceptions don’t apply, and named plaintiffs lack Michigan injury/standing. | Held: Timeliness—Michigan claims are time‑barred (accrued 2006; no adequate affirmative concealment pleaded). Standing—IBEW Local 38 adequately alleged injury to Michigan class members; therefore standing challenge denied. |
| 4) Are California Cartwright Act and UCL claims timely and is unjust enrichment actionable? | Plaintiffs invoke continuing violation, continuous accrual, delayed discovery, and fraudulent concealment to toll limitations. | Defendants argue accrual in 2006, public disclosures put plaintiffs on inquiry, and California does not recognize unjust enrichment as independent cause. | Held: Time‑barred. Accrual in 2006; tolling doctrines inapplicable or inadequately pleaded. California unjust‑enrichment claim dismissed as not an independent cause and time‑barred. |
| 5) Is unjust enrichment claim viable across all states? | Plaintiffs plead unjust enrichment under New York, Michigan, California, and “all states.” | Defendants argue plaintiffs lack standing to assert unjust enrichment for states where named plaintiffs suffered no injury; statutes of limitations vary. | Held: Partially dismissed. New York unjust enrichment survives (six‑year accrual for equitable disgorgement); Michigan and California unjust‑enrichment claims dismissed as untimely or not recognized; out‑of‑state unjust‑enrichment claims dismissed for lack of standing. |
Key Cases Cited
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (plausibility standard for pleadings)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (antitrust pleading standard and plausibility)
- FTC v. Actavis, 133 S. Ct. 2223 (2013) (Supreme Court adopted rule‑of‑reason scrutiny for reverse‑payment settlements)
- Illinois Brick Co. v. Illinois, 431 U.S. 720 (1977) (indirect purchasers barred from seeking treble damages under Clayton Act)
- In re Warfarin Sodium Antitrust Litig., 214 F.3d 395 (3d Cir. 2000) (indirect purchasers may seek injunctive relief under Section 16)